STEPHEN HENRY: Open Payments
NPI 1811925183 · PASADENA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,550 in 174 payments from 32 companies in 2025. Trend: 2023 $3,681 · 2024 $3,494 · 2025 $3,550
Food & beverage: $3,550
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $432 |
| Amgen Inc. | 22 | $294 |
| Bausch Health US, LLC | 18 | $260 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $259 |
| Axsome Therapeutics, Inc. | 10 | $258 |
| Otsuka America Pharmaceutical, Inc. | 11 | $241 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $214 |
| Gilead Sciences, Inc. | 9 | $159 |
| Regeneron Healthcare Solutions, Inc. | 7 | $152 |
| GENZYME CORPORATION | 3 | $118 |
Products named: REXULTI, DUPIXENT, APLENZIN, CAPLYTA, VRAYLAR, OTEZLA, Auvelity, XIFAXAN.
Industry payments across CA — which companies pay providers there.
